Co-Promotion Agreement

Alliance Pharma PLC
09 May 2005


For immediate release                                                9 May 2005

                               ALLIANCE PHARMA PLC
                      ('Alliance Pharma' or 'the Company')

               Announces Co-Promotion Agreement with OralDent Ltd

Alliance Pharma plc (AIM: APH), an emerging speciality pharmaceutical company,
is pleased to announce a co-promotion agreement with OralDent Ltd ('OralDent'),
a privately owned dental products company, for the UK marketing and distribution
of Periostat(R), a prescription medicine for the treatment of the severe gum
disease periodontitis.

Periostat is a major growth opportunity for Alliance Pharma and this agreement
with OralDent marks the first step in the roll-out of the product across the
territories for which the Company holds marketing rights. Alliance Pharma
acquired the rights in November 2004 from CollaGenex International Ltd, part of
CollaGenex Pharmaceuticals Inc (Nasdaq: CGPI), for the territories of the
enlarged European Union, Switzerland, Israel, Australia, New Zealand and South
Africa.

The international roll-out of the product will be led by a senior international
manager, who was recently appointed to head the Company's newly formed
International Division.

OralDent focuses on promoting products to private and NHS dentists in the UK via
a field sales force, a tele-sales operation and an internet portal. Alliance
Pharma will contribute resources to enable OralDent to increase the size of its
sales force to maximise the sales of Periostat. Alliance Pharma will recognise
the Periostat sales and OralDent will receive sales-based royalties on a sliding
scale between 5%per cent and 15% per cent.

Periostat is the first and only approved oral pharmaceutical product for the
adjunctive treatment of adult periodontal disease (periodontitis) by the
suppression of those enzymes that destroy periodontal support tissues. Periostat
is included in the Secretary of State for Health's list for dental prescribing
and is listed on the UK's Dental Practitioners' Formulary. Periodontitis is
estimated to affect 11 per cent of the adult population in the UK.

Commenting, John Dawson, Alliance Pharma's Chief Executive, said: 'Periostat is
a major growth opportunity for the Company and this UK co-promotion agreement is
an important first step in maximising the potential of the product. OralDent has
a particularly strong franchise in the UK dental market and we look forward to a
successful collaboration with them.'

For further information:

Alliance Pharma plc                                   + 44 (0) 1249 466966
John Dawson, Chief Executive
Maddy Scott, Finance Director
www.alliancepharma.co.uk

Numis Securities                                      + 44 (0) 20 7776 1500
Charles Spicer

Buchanan Communications                               + 44 (0) 20 7466 5000
Mark Court/Lisa Baderoon/Rebecca Skye Dietrich

Notes to editors

About Alliance Pharma
Alliance Pharma, founded in 1996, is an AIM listed emerging speciality 
pharmaceutical company based in Chippenham, Wiltshire, UK. The company has a 
strong track record of acquiring the rights to established niche brands and 
owns, or shares, the rights to 30 branded pharmaceutical products and continues 
to explore opportunities to expand the range.

Alliance Pharma's products are prescribed in the treatment of a wide range of 
conditions and include brands used in the prevention of heart disease, in 
Parkinson's disease, in nutrition, in nasal infections, in the treatment of 
dermatological conditions and in childbirth.  Alliance Pharma's sales are mainly 
prescription driven.  Its products are distributed to hospitals directly and to 
pharmaceutical wholesalers which service both hospital and retail pharmacies 
withtheir prescription requirements. Alliance Pharma is also developing new 
products for sleep disorders and the induction of labour.

Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.

About Oraldent Ltd
Oraldent Ltd formed in 1985 is based in St.Neots, Cambridgeshire and is a
subsidiary of Omni Dental sciences Ltd. Oraldent Ltd has a strong brand name
within the professional dental market in the UK. Oraldent specialises in
marketing and distributing high value added dental products which have proven
market and scientific support via its experienced dental marketing and sales
team. Oraldent's product focus is primarily in the preventative market aimed at
helping the UK dental professional to prevent and treat periodontal disease.


                      This information is provided by RNS
            The company news service from the London Stock Exchange